Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Isofol Medical AB ( (SE:ISOFOL) ) is now available.
Isofol Medical AB has announced the final terms for its rights issue and potential overallotment issue, aimed at raising funds for an expanded Phase II study. The rights issue is expected to raise approximately 86 million SEK initially, with additional funds possible through warrants, supporting the company’s efforts to enhance its clinical data and strengthen its position in the oncology sector.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company based in Gothenburg, Sweden, focusing on developing treatments to improve the outlook for cancer patients worldwide. The company is listed on Nasdaq Stockholm and is involved in clinical studies to generate new data for its medical advancements.
Average Trading Volume: 562,276
Current Market Cap: SEK187.8M
For a thorough assessment of ISOFOL stock, go to TipRanks’ Stock Analysis page.